temanogrel oral (APD791 oral) / Pfizer - LARVOL DELTA

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - P2 | N=13 | Terminated | Sponsor: Arena Pharmaceuticals | N=48 ➔ 13 | Recruiting ➔ Terminated; Business decision

Enrollment change • Trial termination • Cardiovascular • Fibrosis • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Arena Pharmaceuticals | Trial primary completion date: Jun 2022 ➔ Oct 2022

Trial primary completion date • Cardiovascular • Fibrosis • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis

Pfizer Completes Acquisition of Arena Pharmaceuticals (Businesswire) - "Pfizer Inc...announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases....Arena has previously indicated that it expected the results of the Phase 3 ELEVATE-UC trial of etrasimod in ulcerative colitis during the first quarter of 2022. Arena’s pipeline also includes two development-stage cardiovascular assets: temanogrel for microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis..."

M&A • Immunology • Inflammatory Bowel Disease • Systemic Sclerosis • Ulcerative Colitis

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - P2; N=48; Recruiting; Sponsor: Arena Pharmaceuticals; Not yet recruiting ➔ Recruiting; Initiation date: Aug 2021 ➔ Nov 2021; Trial primary completion date: Feb 2022 ➔ Jun 2022

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Cardiovascular • Fibrosis • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis (clinicaltrials.gov) - P2; N=48; Not yet recruiting; Sponsor: Arena Pharmaceuticals

Clinical • New P2 trial • Cardiovascular • Fibrosis • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis